欢迎访问中国烧伤创疡杂志网站！

MEBT/MEBO联合自体微粒皮种植在乳腺癌术后皮瓣坏死修复中的应用效果分析
Analysis on The Application Effect of MEBT/MEBO Combined with Autologous Micro-skin Implantation in Repairing Skin Flap Necrosis after Breast Cancer Surgery

刘鹏.MEBT/MEBO联合自体微粒皮种植在乳腺癌术后皮瓣坏死修复中的应用效果分析[J].中国烧伤创疡杂志,2021,(1):37~40.

DOI：

中文关键词: 烧伤创疡再生医疗技术微粒皮种植乳腺癌皮瓣坏死重组人碱性成纤维细胞生长因子血管内皮生长因子表皮细胞生长因子

英文关键词:Regenerative medical technology for burns, wounds and ulcers (MEBT/MEBO) Micro-skin implantation Breast cancer Skin flap necrosis Recombinant human basic fibroblast growth factor (rh-bFGF) Vascular endothelial growth factor (VEGF) Epidermal growth factor (EGF)

基金项目:

作者	单位
刘鹏	安阳市肿瘤医院乳腺外科

摘要点击次数: 1609

全文下载次数: 4182

中文摘要:

目的分析探讨烧伤创疡再生医疗技术（MEBT/MEBO）联合自体微粒皮种植在乳腺癌术后皮瓣坏死修复中的应用效果。方法选取2017年1月至2020年1月安阳市肿瘤医院收治的98例乳腺癌术后皮瓣坏死患者作为研究对象，并按照治疗方法不同将其分为研究组与对照组，每组49例，研究组患者行MEBT/MEBO联合自体微粒皮种植治疗，对照组患者行重组人碱性成纤维细胞生长因子（rh-bFGF）联合自体微粒皮种植治疗，对比两组患者治疗前后创面组织内血管内皮生长因子（VEGF）及表皮细胞生长因子（EGF）水平变化情况以及临床疗效和创面愈合时间。结果治疗后，两组患者创面组织内VEGF及EGF水平均呈逐渐升高的趋势，且各时间点研究组明显高于对照组（治疗第3天：t=2.716、2.187，P=0.008、0.031；治疗第7天：t=2.138、2.624，P=0.035、0.010）；治疗第5周时，研究组患者中痊愈28例、显效14例、有效7例，明显优于对照组的痊愈15例、显效18例、有效12例、无效4例（Z=-3.068，P=0.002）；研究组患者创面愈合时间为（31.34±14.67）d，明显短于对照组患者的创面愈合时间（38.89±15.44）d（t=2.481，P=0.015）。结论与rh-bFGF联合自体微粒皮种植治疗相比，MEBT/MEBO联合自体微粒皮种植可明显提高乳腺癌术后皮瓣坏死患者创面组织内VEGF、EGF的表达水平，促进创面愈合，缩短创面愈合时间，疗效显著。

英文摘要:

【Abstract】Objective To analyze the application effect of the regenerative medical technology for burns, wounds and ulcers (MEBT/MEBO) combined with autologous micro-skin implantation in repairing skin flap necrosis following breast cancer surgery. Methods Ninety-eight patients with skin flap necrosis after breast cancer surgery, admitted to Anyang Cancer Hospital from January 2017 to January 2020, were selected as research subjects and divided, according to different treatments they received, into a study group and a control group, 49 cases each group. Patients in the study group were treated with MEBT/MEBO combined with autologous micro-skin implantation, whereas patients in the control group were treated with recombinant human basic fibroblast growth factor (rh-bFGF) combined with micro-skin implantation. Changes in levels of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) before and after treatment, as well as clinical efficacy and wound healing time were compared between the two groups. Results After treatment, the levels of VEGF and EGF in the wound tissues of the patients in the two groups all presented a trend of gradual increase, and their levels at each time point in the study group were significantly higher than that in the control group (Day 3 of treatment: t = 2.716, 2.187, P = 0.008, 0.031; day 7 of treatment: t = 2.138, 2.624, P = 0.035, 0.010). At week 5 of treatment, 28 cases were cured, 14 cases presented markedly effective and 7 cases effective in the study group, which were significantly better than that in the control group (15 cases cured and 18 cases markedly effective, 12 cases effective, and 4 cases ineffective) (Z= -3.068, P = 0.002). The wound healing time in the study group was (31.34±14.67) days, which was significantly shorter than that in the control group - (38.89±15.44) days (t=2.481, P=0.015). Conclusion Compared with the treatment protocol of rh-bFGF combined with autologous micro-skin implantation, the protocol of MEBT/MEBO combined with autologous micro-skin implantation is better in increasing the expression levels of VEGF and EGF in wound tissues of patients with skin flap necrosis after breast cancer surgery, promoting wound healing and shortening the wound healing time.